Trial intelligence / Profile preview

Phase II randomized double-blind placebo-controlled trial of OT202 eye drops in moderate-to-severe dry eye

CTR20223244Phase 2Completed

Sponsor
Ocumension Biotech
Start
Dec 2022
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of OT-202 in dry eye syndrome (DED), sponsored by Ocumension Biotech. Started Dec 2022; status: completed.

02

Drugs

OT-202
03

Conditions

dry eye syndrome (DED)

Beyond the preview

Go deeper on CTR20223244.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20223244.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call